Selecta Biosciences Inc (NASDAQ:SELB) has received an average rating of “Hold” from the eight analysts that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $31.75.
SELB has been the subject of a number of recent analyst reports. Zacks Investment Research cut shares of Selecta Biosciences from a “hold” rating to a “sell” rating in a research report on Wednesday, August 29th. Stifel Nicolaus initiated coverage on shares of Selecta Biosciences in a research report on Friday, September 14th. They issued a “buy” rating and a $24.00 price objective for the company. BidaskClub cut shares of Selecta Biosciences from a “buy” rating to a “hold” rating in a research report on Thursday, August 16th. Mizuho restated a “buy” rating and issued a $30.00 price objective on shares of Selecta Biosciences in a research report on Thursday, August 9th. Finally, Canaccord Genuity restated a “buy” rating and issued a $40.00 price objective on shares of Selecta Biosciences in a research report on Wednesday, July 11th.
SELB opened at $13.31 on Tuesday. The company has a debt-to-equity ratio of 0.87, a current ratio of 4.96 and a quick ratio of 4.96. Selecta Biosciences has a 12 month low of $7.95 and a 12 month high of $24.02. The firm has a market capitalization of $348.26 million, a P/E ratio of -4.16 and a beta of -3.47.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Northern Trust Corp increased its position in shares of Selecta Biosciences by 11.9% in the 2nd quarter. Northern Trust Corp now owns 156,708 shares of the company’s stock valued at $2,076,000 after buying an additional 16,615 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Selecta Biosciences by 27.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 47,273 shares of the company’s stock valued at $626,000 after buying an additional 10,114 shares in the last quarter. Millennium Management LLC bought a new position in Selecta Biosciences during the 2nd quarter worth about $1,583,000. Proxima Capital Management LLC bought a new position in Selecta Biosciences during the 2nd quarter worth about $1,075,000. Finally, BlackRock Inc. increased its holdings in Selecta Biosciences by 40.4% during the 2nd quarter. BlackRock Inc. now owns 884,564 shares of the company’s stock worth $11,721,000 after purchasing an additional 254,586 shares in the last quarter. Institutional investors and hedge funds own 48.74% of the company’s stock.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.
Read More: Penny Stocks, Risk and Reward Factors
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.